Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with

Francesca Buchi1, Roberta Pastorelli, Germano Ferrari

  • 1Functional Unit of Haematology, Department of Experimental Pathology and Oncology, University of Florence, Florence, Italy.

Leukemia Research
|March 9, 2011
PubMed

Chronic myeloid leukaemia has a specific therapy: BCR/ABL inhibitor imatinib. Resistance due to BCR/ABL dependent and independent mechanisms is partially reversible by histone deacetylase inhibitors. We analysed by 2D-electrophoresis and anti-pan-acetylated and anti-phosphotyrosine immunoblots, followed by spot-matching and MALDI-TOF mass spectrometry, which proteome modifications would parallel restoration of sensitivity to imatinib by valproic acid (VPA). VPA plus imatinib significantly increased acetylation of HSP90 and hnRNP L and decreased phosphorylation of HSPs and hnRNPs in imatinib resistant cells. VPA was able to modify profoundly acetylome and phosphoproteome of CML cells, while reverting resistance to imatinib.